The steroid-sparing effect of an Emollient APDDR-0801 in patients with atopic dermatitis

Seongmin Noh, Jin Young Jung, Won Seok Park, Hyun Ju Koh, Kwang Hoon Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Defective skin barrier function is a well recognized feature in atopic dermatitis (AD) and causes symptoms such as xerosis, pruritus and erythematous lesions. Since moisturizers can strengthen a defective skin barrier and reduce the usage of corticosteroid cream, the choice of moisturizer is very significant for AD patients. Objective: This study was done to compare the steroid-sparing effects of a ceramide-containing moisturizer, APDDR-0801, with a control moisturizer without ceramide, for relieving symptoms associated with AD. Methods: A randomized, controlled, double-blinded 6-week study was conducted. Patients with mild to moderate AD topically applied APDDR-0801 or the control moisturizer on the whole body for 6 weeks. They also applied corticosteroid cream (Zemaderm®) on the lesion twice daily for 6 weeks. The amount of corticosteroid used was measured by weighing the tubes. Disease severity was evaluated by eczema severity, area index (EASI), and investigator global assessment (IGA). Transepidermal water loss (TEWL) and skin capacitance were also measured. Results: Of the 40 patients enrolled, 32 completed the protocol. The mean age was (12.95±1.92) and the average baseline EASI score was (10.45±1.17). EASI score, IGA, TEWL and skin capacitance improved in both groups at 3 weeks and 6 weeks. Compared to the control group, the amount of steroid cream used at 3 weeks and 6 weeks decreased by 0.14 g (?18.78%) and 0.76 g (?7.46%), respectively, in the test group. The difference was larger in patients with moderate AD. The consumption of steroids was lower in the test group at 3 weeks [2.65 g (?34.64%)] and at 6 weeks [2.60 g (?19.38%)], respectively. Conclusion: The moisturizer APDDR-0801 (Atobarrier cream®) which contains physiologic lipid granules including ceramide, has superior steroid-sparing effects than moisturizers without ceramide.

Original languageEnglish
Pages (from-to)227-233
Number of pages7
JournalKorean Journal of Dermatology
Volume49
Issue number3
Publication statusPublished - 2011 Mar 1

Fingerprint

Emollients
Atopic Dermatitis
Ceramides
Steroids
Eczema
Skin
Adrenal Cortex Hormones
Research Personnel
Water
Pruritus
Lipids
Control Groups

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Noh, Seongmin ; Jung, Jin Young ; Park, Won Seok ; Koh, Hyun Ju ; Lee, Kwang Hoon. / The steroid-sparing effect of an Emollient APDDR-0801 in patients with atopic dermatitis. In: Korean Journal of Dermatology. 2011 ; Vol. 49, No. 3. pp. 227-233.
@article{7d090b6cac8249f8861f752fca585918,
title = "The steroid-sparing effect of an Emollient APDDR-0801 in patients with atopic dermatitis",
abstract = "Background: Defective skin barrier function is a well recognized feature in atopic dermatitis (AD) and causes symptoms such as xerosis, pruritus and erythematous lesions. Since moisturizers can strengthen a defective skin barrier and reduce the usage of corticosteroid cream, the choice of moisturizer is very significant for AD patients. Objective: This study was done to compare the steroid-sparing effects of a ceramide-containing moisturizer, APDDR-0801, with a control moisturizer without ceramide, for relieving symptoms associated with AD. Methods: A randomized, controlled, double-blinded 6-week study was conducted. Patients with mild to moderate AD topically applied APDDR-0801 or the control moisturizer on the whole body for 6 weeks. They also applied corticosteroid cream (Zemaderm{\circledR}) on the lesion twice daily for 6 weeks. The amount of corticosteroid used was measured by weighing the tubes. Disease severity was evaluated by eczema severity, area index (EASI), and investigator global assessment (IGA). Transepidermal water loss (TEWL) and skin capacitance were also measured. Results: Of the 40 patients enrolled, 32 completed the protocol. The mean age was (12.95±1.92) and the average baseline EASI score was (10.45±1.17). EASI score, IGA, TEWL and skin capacitance improved in both groups at 3 weeks and 6 weeks. Compared to the control group, the amount of steroid cream used at 3 weeks and 6 weeks decreased by 0.14 g (?18.78{\%}) and 0.76 g (?7.46{\%}), respectively, in the test group. The difference was larger in patients with moderate AD. The consumption of steroids was lower in the test group at 3 weeks [2.65 g (?34.64{\%})] and at 6 weeks [2.60 g (?19.38{\%})], respectively. Conclusion: The moisturizer APDDR-0801 (Atobarrier cream{\circledR}) which contains physiologic lipid granules including ceramide, has superior steroid-sparing effects than moisturizers without ceramide.",
author = "Seongmin Noh and Jung, {Jin Young} and Park, {Won Seok} and Koh, {Hyun Ju} and Lee, {Kwang Hoon}",
year = "2011",
month = "3",
day = "1",
language = "English",
volume = "49",
pages = "227--233",
journal = "Korean Journal of Dermatology",
issn = "0494-4739",
publisher = "Korean Dermatological Association",
number = "3",

}

The steroid-sparing effect of an Emollient APDDR-0801 in patients with atopic dermatitis. / Noh, Seongmin; Jung, Jin Young; Park, Won Seok; Koh, Hyun Ju; Lee, Kwang Hoon.

In: Korean Journal of Dermatology, Vol. 49, No. 3, 01.03.2011, p. 227-233.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The steroid-sparing effect of an Emollient APDDR-0801 in patients with atopic dermatitis

AU - Noh, Seongmin

AU - Jung, Jin Young

AU - Park, Won Seok

AU - Koh, Hyun Ju

AU - Lee, Kwang Hoon

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background: Defective skin barrier function is a well recognized feature in atopic dermatitis (AD) and causes symptoms such as xerosis, pruritus and erythematous lesions. Since moisturizers can strengthen a defective skin barrier and reduce the usage of corticosteroid cream, the choice of moisturizer is very significant for AD patients. Objective: This study was done to compare the steroid-sparing effects of a ceramide-containing moisturizer, APDDR-0801, with a control moisturizer without ceramide, for relieving symptoms associated with AD. Methods: A randomized, controlled, double-blinded 6-week study was conducted. Patients with mild to moderate AD topically applied APDDR-0801 or the control moisturizer on the whole body for 6 weeks. They also applied corticosteroid cream (Zemaderm®) on the lesion twice daily for 6 weeks. The amount of corticosteroid used was measured by weighing the tubes. Disease severity was evaluated by eczema severity, area index (EASI), and investigator global assessment (IGA). Transepidermal water loss (TEWL) and skin capacitance were also measured. Results: Of the 40 patients enrolled, 32 completed the protocol. The mean age was (12.95±1.92) and the average baseline EASI score was (10.45±1.17). EASI score, IGA, TEWL and skin capacitance improved in both groups at 3 weeks and 6 weeks. Compared to the control group, the amount of steroid cream used at 3 weeks and 6 weeks decreased by 0.14 g (?18.78%) and 0.76 g (?7.46%), respectively, in the test group. The difference was larger in patients with moderate AD. The consumption of steroids was lower in the test group at 3 weeks [2.65 g (?34.64%)] and at 6 weeks [2.60 g (?19.38%)], respectively. Conclusion: The moisturizer APDDR-0801 (Atobarrier cream®) which contains physiologic lipid granules including ceramide, has superior steroid-sparing effects than moisturizers without ceramide.

AB - Background: Defective skin barrier function is a well recognized feature in atopic dermatitis (AD) and causes symptoms such as xerosis, pruritus and erythematous lesions. Since moisturizers can strengthen a defective skin barrier and reduce the usage of corticosteroid cream, the choice of moisturizer is very significant for AD patients. Objective: This study was done to compare the steroid-sparing effects of a ceramide-containing moisturizer, APDDR-0801, with a control moisturizer without ceramide, for relieving symptoms associated with AD. Methods: A randomized, controlled, double-blinded 6-week study was conducted. Patients with mild to moderate AD topically applied APDDR-0801 or the control moisturizer on the whole body for 6 weeks. They also applied corticosteroid cream (Zemaderm®) on the lesion twice daily for 6 weeks. The amount of corticosteroid used was measured by weighing the tubes. Disease severity was evaluated by eczema severity, area index (EASI), and investigator global assessment (IGA). Transepidermal water loss (TEWL) and skin capacitance were also measured. Results: Of the 40 patients enrolled, 32 completed the protocol. The mean age was (12.95±1.92) and the average baseline EASI score was (10.45±1.17). EASI score, IGA, TEWL and skin capacitance improved in both groups at 3 weeks and 6 weeks. Compared to the control group, the amount of steroid cream used at 3 weeks and 6 weeks decreased by 0.14 g (?18.78%) and 0.76 g (?7.46%), respectively, in the test group. The difference was larger in patients with moderate AD. The consumption of steroids was lower in the test group at 3 weeks [2.65 g (?34.64%)] and at 6 weeks [2.60 g (?19.38%)], respectively. Conclusion: The moisturizer APDDR-0801 (Atobarrier cream®) which contains physiologic lipid granules including ceramide, has superior steroid-sparing effects than moisturizers without ceramide.

UR - http://www.scopus.com/inward/record.url?scp=79960907971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960907971&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79960907971

VL - 49

SP - 227

EP - 233

JO - Korean Journal of Dermatology

JF - Korean Journal of Dermatology

SN - 0494-4739

IS - 3

ER -